| Literature DB >> 33468406 |
Mohammad Hessam Rafiee1, Sedigheh Amini Kafiabad2, Mahtab Maghsudlu1.
Abstract
BACKGROUND: With the outbreak of the coronavirus disease in 2019, called COVID-19, Iranian Blood Transfusion Organization (IBTO) implemented the new deferrals. This study analyzed the COVID-19 deferrals of blood volunteers and compared the demographics, deferrals, and the donor status during the COVID-19 outbreak in 2019. STUDY DESIGN AND METHODS: Data were collected from the integrated blood donor database between Feb-Apr 2019 and 2020. Deferral reasons of COVID-19 were categorized as: those who have symptoms or live with a symptomatic family member, have direct exposure with a confirmed case, have travelled from the outbreak affected areas, and have fully recovered from confirmed COVID-19. The z-test analysis was used, and 95 % confidence intervals were calculated to compare the sample proportions.Entities:
Keywords: Blood donors; COVID-19; Donor selection; Temporary deferrals
Mesh:
Year: 2021 PMID: 33468406 PMCID: PMC7833597 DOI: 10.1016/j.transci.2020.103049
Source DB: PubMed Journal: Transfus Apher Sci ISSN: 1473-0502 Impact factor: 1.764
Comparison of data between 2019 and 2020 in a similar time frame (20 Feb- 19 Apr 2020). Total registration and blood donation, total deferrals, demographic characteristics (age and sex) and donor status history were compared.
| Variables | 2019 N (%)§ | 2020 N (%)§ | Percent change (%)¥ | Growth rate (%)# | Z-test analysis* between 2020 to 2019 | Statistics for COVID-19 deferrals (%)£ |
|---|---|---|---|---|---|---|
| 409,231 | 312,056 | – | −23.74 | – | – | |
| 343,163(83.86) | 253,644(81.28) | −3.08 | −26.09 | 0.0001 | – | |
| | 39,987 (11.65) | 36,450 (14.37) | + 23.35 | −8.84 | 0.0001 | 519 (1.42) |
| | 6918 (2.01) | 3277 (1.29) | −35.82 | −52.63 | 10 (0.30) | |
| | 101,539 (29.59) | 71,700 (28.27) | −4.46 | −29.39 | 0.0001 | 540 (0.75) |
| | 194,719 (56.74) | 142,217(56.07) | −1.18 | −29.96 | 0.0001 | 742 (0.52) |
| | 13,572 (3.95) | 13,472 (5.31) | + 34.43 | −0.74 | 0.00001 | 147 (1.09) |
| | 329,591 (96.05) | 240,172(94.69) | −1.41 | −27.l3 | 0.00001 | 1664 (0.69) |
| | 23,296 (6.79) | 18,115 (7.14) | + 5.15 | −22.24 | 0.16152 | 119 (0.65) |
| | 101,515 (29.58) | 70,888 (27.95) | −5.51 | −30.17 | 0.0001 | 524 (0.74) |
| | 117,586 (34.26) | 87,337 (34.43) | + 0.50 | −25.72 | 0.4295 | 629 (0.71) |
| | 74,870 (21.82) | 58,794 (23.18) | + 6.23 | −21.47 | 0.00001 | 404 (0.69) |
| | 25,896 (7.55) | 18,510 (7.30) | −3.31 | −28.52 | 0.32708 | 135 (0.73) |
| 12,234 | 7699 | −17.39 | −37.07 | 0.02926 | – | |
| 53,834 | 50,713 | + 23.57 | −5.80 | 0.00001 | 1811 |
PDLS: pre-donation laboratory screening.Total registration was the bases to calculate the percentages for total donation and deferrals and total donation was the bases to calculate the percentages for donor status, sex, and age-groups. The percent change between two percentages in 2020 compared to 2019. Growth rate: decrease in 2020 compared to 2019. *p ≤ 0.05 was significant. Total statistics in 2020 column was the bases to calculate the percentages for COVID-19 deferrals.
Demographic characteristics and donor status based on deferrals related to COVID-19 (20 Feb-19 Apr 2020). Deferrals I-V for COVID-19 described in section of materials and methods.
| First 30-day (20 Feb-19 Mar) | Second 30-day (20 Mar-19 Apr) | 20 Feb-19 Apr | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | ||||||||||||||||||
| 74 | 3 | 2 | 83 | 0 | 162 | 184 | 23 | 23 | 97 | 30 | 357 | 258 | 26 | 25 | 180 | 30 | 519 (28.66) | |
| 2 | 0 | 0 | 1 | 0 | 3 | 2 | 0 | 1 | 3 | 1 | 7 | 4 | 0 | 1 | 4 | 1 | 10 (0.55) | |
| 60 | 2 | 1 | 92 | 0 | 155 | 208 | 24 | 25 | 104 | 24 | 385 | 268 | 26 | 26 | 196 | 24 | 540 (29.82) | |
| 118 | 8 | 7 | 154 | 2 | 289 | 224 | 30 | 44 | 132 | 23 | 453 | 342 | 38 | 51 | 286 | 25 | 742 (40.97) | |
| 17 | 0 | 0 | 20 | 0 | 37 | 59 | 9 | 7 | 27 | 8 | 110 | 76 | 9 | 7 | 47 | 8 | 147 (8.12) | |
| 237 | 13 | 10 | 310 | 2 | 572 | 559 | 68 | 86 | 309 | 70 | 1092 | 796 | 81 | 96 | 619 | 72 | 1664(91.88) | |
| 15 | 0 | 0 | 28 | 0 | 43 | 41 | 3 | 12 | 17 | 3 | 76 | 56 | 3 | 12 | 45 | 3 | 119 (6.57) | |
| 76 | 5 | 6 | 99 | 1 | 187 | 169 | 17 | 20 | 114 | 17 | 337 | 245 | 22 | 26 | 213 | 18 | 524 (28.93) | |
| 91 | 7 | 3 | 120 | 1 | 222 | 202 | 26 | 36 | 125 | 18 | 407 | 293 | 33 | 39 | 245 | 19 | 629 (34.73) | |
| 52 | 1 | 1 | 58 | 0 | 112 | 163 | 20 | 22 | 58 | 29 | 292 | 215 | 21 | 23 | 116 | 29 | 404 (22.30) | |
| 20 | 0 | 0 | 25 | 0 | 45 | 43 | 11 | 3 | 22 | 11 | 90 | 63 | 11 | 3 | 47 | 11 | 135 (7.45) | |
| 254 | 13 | 10 | 330 | 2 | 609 | 618 | 77 | 93 | 336 | 78 | 1202 | 872 | 90 | 103 | 666 | 80 | 1811 | |
| (41.71) | (2.13) | (1.64) | (54.19) | (0.33) | (51.41) | (6.41) | (7.74) | (27.95) | (6.49) | (48.15) | (4.97) | (5.69) | (36.77) | (4.42) | ||||
Deferral type: I. Having a fever and symptoms of a respiratory illness in the past 28 days; II. Having a family member in the house with a fever and respiratory symptoms in the past 28 days; III. Having a close contact with someone who is diagnosed with confirmed COVID-19 in the past 28 days IV; Having travel record to a region that has been high risk for COVID-19 (an area with highly prevalent COVID-19 cases) in the past 28 days; V. The volunteers who have been diagnosed with COVID-19 (after recovery and the resolution of symptoms).
PDLS: pre-donation laboratory screening.
The percentage for deferral type related to COVID-19 was separately calculated of total deferral in each time period (first 30-day and second 30-day).
The comparative analysis of COVID-19 deferrals of the first and second 30-day of the study.
| Deferral type | First 30-day (20 Feb-19 Mar) | Second 30-day (20 Mar-19 Apr) | P | ||
|---|---|---|---|---|---|
| No of deferrals | Deferral per total registration (CI 95 %) | No of deferrals | Deferral per total registration (CI 95 %) | ||
| 254 | 2204 (1945−2488) | 618 | 4465 (4123−4828) | P <0.05 | |
| 13 | 112 (62−188) | 77 | 556 (442−691) | P <0.05 | |
| 10 | 86 (44−154) | 93 | 671 (545−819) | P <0.05 | |
| 330 | 2864 (2567−3186) | 336 | 2428 (2178−2698) | N.S | |
| 2 | 17 (3−57) | 78 | 563 (448−699) | P <0.05 | |
Deferral type: I. Having a fever and symptoms of a respiratory illness in the past 28 days; II. Having a family member in the house with a fever and respiratory symptoms in the past 28 days; III. Having a close contact with someone who is diagnosed with confirmed COVID-19 in the past 28 days IV; Having travel record to a region that has been high risk for COVID-19 (an area with highly prevalent COVID-19 cases) in the past 28 days; V. The volunteers who have been diagnosed with COVID-19 (after recovery and the resolution of symptoms).
The numbers were calculated as deferral number per 106 registrations. The confidence interval 95 % for deferral type related to COVID-19 was separately calculated of total registration in first 30-day (n = 115,231) and in second 30-day (n = 138,413).
p ≤ 0.05 was significant. N.S: non-significant. The total deferral for COVID-19 in the second 30-day (n = 1202) was about twice as high as in the first 30-day (n = 609).
Fig. 1Trend of COVID-19 Laboratory-Confirmed Cases and Deaths in the general population of Iran. (Adopted from a report update from WHO Regional Director for Eastern Mediterranean, table of confirmed cases in the EMR Countries. 24 July 2020).